Picture of Hugel logo

145020 — Hugel News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeMid CapFalling Star

Brief: Hugel Resubmits BLA For Its Botulinum Toxin, Letybo To The U.S. FDA

Sept 1 (Reuters) - Hugel Inc  145020.KQ :
    * HUGEL RESUBMITS BLA FOR ITS BOTULINUM TOXIN, LETYBO TO THE
U.S.
FDA
    * HUGEL INC - EXPECTED TO OBTAIN U.S. FDA'S APPROVAL IN Q1
OF 2024
    * HUGEL INC - RESUBMITTED BLA AFTER COMPLETING A REVIEW OF
FACILITY MANAGEMENT AND SUPPLEMENTARY WORK IN-LINE WITH CRL
REQUESTS RECEIVED FROM FDA

Source text for Eikon:  ID:nPn8CgPbha 
Further company coverage:  145020.KQ

Recent news on Hugel

See all news